SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

That was a follow up to this analyst

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
cjstocksup Member Profile
Member Level 
Followed By 2,901
Posts 209,150
Boards Moderated 2
Alias Born 07/30/07
160x600 placeholder
Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain "NetworkNewsWire" - 12/13/2017 8:45:00 AM
Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management "NetworkNewsWire" - 12/6/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/4/2017 7:31:33 AM
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 ... "GlobeNewswire Inc." - 12/3/2017 12:01:00 PM
Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES) "GlobeNewswire Inc." - 11/21/2017 9:00:00 AM
Innovation Drives Value for Leading Cannabis Biotechs "NetworkNewsWire" - 11/15/2017 8:45:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/14/2017 8:03:15 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/14/2017 7:31:54 AM
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights "GlobeNewswire Inc." - 11/14/2017 7:30:00 AM
Biotech M&A Momentum Attractive for Cannabinoid R&D Space "NetworkNewsWire" - 11/7/2017 8:45:00 AM
Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences "GlobeNewswire Inc." - 11/7/2017 7:30:00 AM
Economic Impact of Biosynthesis on the Cannabis Industry "NetworkNewsWire" - 10/31/2017 8:45:00 AM
Innovative Biotechnology Companies are Transforming Cannabis-based Medical Products "NetworkNewsWire" - 10/26/2017 8:45:00 AM
How Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals "NetworkNewsWire" - 10/24/2017 8:45:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/23/2017 7:26:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 8:01:50 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:09:06 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:08:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:07:22 PM
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development "NetworkNewsWire" - 9/28/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/28/2017 7:02:33 AM
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile... "GlobeNewswire Inc." - 9/28/2017 6:30:00 AM
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development "NetworkNewsWire" - 9/26/2017 8:45:00 AM
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects "NetworkNewsWire" - 9/19/2017 8:45:00 AM
Biosynthesis Technology Could Transform Cannabinoid Production "NetworkNewsWire" - 9/13/2017 8:45:00 AM
cjstocksup Member Level  Tuesday, 10/03/17 12:53:46 AM
Re: cjstocksup post# 901
Post # of 1013 
That was a follow up to this analyst upgrade to Overweight and $17.00 per share ZYNE PPS target.
ZYNE upgraded to $17.00. Look for more of these.
UPDATE: Cantor Fitzgerald Upgrades Zynerba Pharmaceuticals (ZYNE) to Overweight
October 2, 2017 5:55 AM

(Updated - October 2, 2017 6:54 AM EDT)


(updated to add analyst comment)

Cantor Fitzgerald upgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Neutral to Overweight with a price target of $17.00 (from $4.00).

Analyst Elemer Piros cites the phase 2a data in Fragile X syndrome noting encouragement from the potential for ZYN002 in treating the disease. The analyst sees upside catalysts from additional regulatory clarity on late-stage development which is slated for 2018.

For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.

Shares of Zynerba Pharmaceuticals closed at $8.36 Friday.
https://www.streetinsider.com/dr/news.php?id=13346899&gfv=1


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist